VSY Biotechnology announced that it is moving its headquarters from the Netherlands to Germany. VSY Biotechnology GmbH will be the company’s new headquarters.
VSY Biotechnology commenced operations in the late 90s. Since then, the company has achieved several milestones on the way to becoming a global player in the innovation-driven medical device sector.
Applications for this year’s Ophthalmology Star Awards (OSA), organized annually by VSY Biotechnology, will continue until July 15, 2020.
As part of the Ophthalmology Star Awards (OSA), articles by ophthalmologists published in English since January 2019 are being evaluated by an international jury. Ophthalmologists can apply for the contest until July 15, 2020,
VSY Biotechnology Research Center has developed a strong R&D program in various areas of biotechnology and is now proud to announce its latest achievement: TR-C 19, a drug to treat COVID-19.
At VSY Biotechnology, we are very excited to announce that a new drug, named TR-C 19, has been developed to treat COVID-19 by the VSY Biotechnology R&D team.
Dr. Fatih Ergin, CEO of VSY Biotechnology, stated that traditional roles and models worldwide will be completely transformed by the traumatic impact of the coronavirus and added that “the 21st century has just started now.”
Dr. Fatih Ergin, CEO of VSY Biotechnology, stated that the company anticipates that the coronavirus pandemic, which has led to many losses of life,
World’s First and Only Sinusoidal Trifocal Optical Designed Intraocular Lens Acriva Trinova has Been Registered by the Euroepean Patent Office
European Patent Office (EPO) has issued the decision of appropriate for patent for world’s first and only intraocular lens produced with Sinusoidal Vision Technology (SVT) by VSY Biotechnology.
In the year 2018,
With its booth, and scientific and social events, VSY Biotechnology was the center of attention at the 37th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), the world’s premier ophthalmology event. VSY Biotechnology organized the Stars of Ophthalmology Award Ceremony, presented the awards to the finalists, and attracted a great deal of attention in Paris on September 14–18,
VSY Biotechnology invests in a faster and more efficient supply chain in Europe.
VSY Biotechnology, with head offices in the Netherlands, Spain, and Germany, has strengthened its network with new logistics centers in Europe. The company opened a new logistics center in Germany on 20 August 2019. A new online ordering system was commissioned at the beginning of the year.
VSY Biotechnology’s invention, the Rotaryjet Preloaded Injector containing an accessory system for the storage and injection of an intraocular lens, has been registered by the European Patent Institute (EPI). This newly patented technology minimises the use of viscoelastic material in intraocular lens implantation and provides ultimate ease of use.
The Rotaryjet Preloaded Injector,
ESCRS Board Member Prof.Dr. Ewa Mrukwa-Kominek told that Acriva Trinova implanted patients do not experience glare and halos and have very sharp visual equity.
Halos are bright circles that surround a light source, like headlights. Glare is light that enters your eye and interferes with your vision. These vision problems can be very disturbing even disabling after a cataract surgery.
VSY Biotechnology is now accepting applications for the Ophthalmology Star Awards.
The Stars of Ophthalmology will be selected among the applicants who have a scientific article published in an ophthalmology journal since January 2018.
The articles are required to be authored in English and already published in order to be eligible for the Ophthalmology Star Awards.